This project is a collaboration between the WearOptimo™ enterprise, The Australian National University, Queensland Government, Johnson & Johnson Innovation and ANFF.
Microwearable™ personalised diagnostic wearable devices have the opportunity to be a cornerstone of precision medicine by offering personalised diagnostics across a range of diseases. These devices are minimally-invasive, pain-free sensors applied to the skin to access key biomarkers and biosignals – for both episodic and continuous monitoring.
In doing so, Microwearable™ personalised diagnostic devices aim to leapfrog traditional diagnostics: based on lab-based assays of blood samples and histopathology – with the costs, risks and time-delays. The WearOptimo™ Enterprise will be developed as a fit-for-purpose enterprise to rapidly compete at scale, meeting the unique opportunity at the nexus of three growing markets: IoT for medicine; personalised medicine; and wearable devices for healthcare.
Led by Professor Mark Kendall and in partnership with the Australian National University (ANU), this project will take the next critical step in working to advance WearOptimo™ Enterprise that is commercial, with a technical proof-of-concept, and is investor ready.